Estradiol Doesn't Boost Cognitive Function After Menopause

This article originally appeared here.
Share this content:
Estradiol Doesn't Boost Cognitive Function After Menopause
Estradiol Doesn't Boost Cognitive Function After Menopause

THURSDAY, July 21, 2016 (HealthDay News) -- Improvement in cognitive ability is not associated with estrogen therapy among women who use it after menopause, no matter when they start taking it, according to a study published online July 15 in Neurology.

Victor Henderson, M.D., of the Stanford University School of Medicine in Palo Alto, Calif., and colleagues randomly assigned 567 healthy women, aged 41 to 84, to take estradiol or an inactive placebo every day. In addition, the women were divided into two groups: an early menopause group (within six years of their last period) and a late group (at least 10 years after menopause). The women also used a vaginal progesterone gel or placebo gel, unless they had had a hysterectomy. The average treatment lasted nearly five years. The investigators tested the verbal memory and cognitive skills of the participants at the beginning of the trial, 2.5 years later, and five years later.

The researchers found that, compared with starting scores on memory tests, women improved in verbal memory with practice, with and without hormone therapy. Scores were the same for those with and without hot flashes, and for women who had a uterus or had a hysterectomy.

"Estradiol initiated within six years of menopause does not affect verbal memory, executive functions, or global cognition differently than therapy begun 10+ years after menopause," the authors write. "Estradiol neither benefits nor harms these cognitive abilities regardless of time since menopause."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »